These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38420062)

  • 1. The Efficacy and Safety of High Dose (10 mg) of Desloratadine (Dazit® 10) in the Treatment of Chronic Spontaneous Urticaria in India: A Phase III, Multicentric, Open-Label, Single-Arm Study.
    Kapadia S; Nageswaramma S; Shah K; Singh A; Mahajan SC; Deshpande A; Chakraborty S; Kar BR; Padmaja P; Bharija SC; Doshi M; Ghadge P; Gabhane M; Dharmadhikari S; Mane A; Mehta S
    Cureus; 2024 Jan; 16(1):e53125. PubMed ID: 38420062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.
    Rossi O; Piccirillo A; Iemoli E; Patrizi A; Stingeni L; Calvieri S; Gola M; Dapavo P; Cristaudo A; Zichichi L; Losappio L; Saccheri F; Pastorello EA
    World Allergy Organ J; 2020 Dec; 13(12):100470. PubMed ID: 33343800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
    Potter P; Mitha E; Barkai L; Mezei G; Santamaría E; Izquierdo I; Maurer M
    Pediatr Allergy Immunol; 2016 Feb; 27(1):55-61. PubMed ID: 26267219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
    Bachert C; Maurer M
    Clin Drug Investig; 2010; 30(2):109-22. PubMed ID: 20067329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
    Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
    World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
    Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
    World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.
    Yan S; Chen W; Wen S; Zhu W; Guo A; Chen X; Zhang C; Chen M; Zhang J; Su J; Zhao Y; He Y; Liu Z; Zhou H; Zeng W; Li J; Chen X
    J Dermatol Sci; 2014 Dec; 76(3):240-5. PubMed ID: 25455139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.
    Cherrez-Ojeda I; Maurer M; Bernstein JA; Vanegas E; Felix M; Ramon GD; Ensina LF; Larco Sousa JI; Matos Benavides EE; Cardona Villa R; Latour Staffeld P; Morfin-Maciel BM; Mori J; Wilches C P; Mata VL; Cherrez A
    World Allergy Organ J; 2019; 12(2):100011. PubMed ID: 30937137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea.
    Ye YM; Koh YI; Choi JH; Kim MA; Park JW; Kim TB; Nam YH; Chang YS; Park HS
    Korean J Intern Med; 2022 Sep; 37(5):1050-1060. PubMed ID: 36068718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Refractoriness to an Up to Fourfold Dosage of Antihistamines in Isolated Chronic Spontaneous Urticaria.
    Wongjirattikarn R; Chaowattanapanit S; Foocharoen C; Sawanyawisuth K; Choonhakarn C; Julanon N; Utchariyaprasit E
    J Cutan Med Surg; 2022; 26(6):593-599. PubMed ID: 36172833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study.
    Kim H; Lynde C
    Arch Drug Inf; 2008 Sep; 1(2):63-69. PubMed ID: 19915710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.
    DuBuske L
    Am J Clin Dermatol; 2007; 8(5):271-83. PubMed ID: 17902729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of patient-reported outcomes in the management of chronic spontaneous urticaria.
    Hopkinson K
    Br J Nurs; 2019 Feb; 28(3):144-150. PubMed ID: 30746981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial.
    Metz M; Weller K; Neumeister C; Izquierdo I; Bödeker RH; Schwantes U; Maurer M
    Dermatol Ther (Heidelb); 2015 Dec; 5(4):217-230. PubMed ID: 26591001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
    Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
    Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.